Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non–small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial
U Gatzemeier, A Pluzanska, A Szczesna… - Journal of Clinical …, 2007 - ascopubs.org
Purpose Erlotinib is a potent inhibitor of the epidermal growth factor receptor tyrosine kinase,
with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of …
with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of …
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.
U Gatzemeier, A Pluzanska, A Szczesna… - Journal of Clinical …, 2007 - europepmc.org
Purpose Erlotinib is a potent inhibitor of the epidermal growth factor receptor tyrosine kinase,
with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of …
with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of …
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial
U Gatzemeier, A Pluzanska… - Journal of clinical …, 2007 - pubmed.ncbi.nlm.nih.gov
Purpose Erlotinib is a potent inhibitor of the epidermal growth factor receptor tyrosine kinase,
with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of …
with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of …
[PDF][PDF] Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation …
U Gatzemeier, A Pluzanska, A Szczesna, E Kaukel… - J Clin …, 2007 - researchgate.net
Purpose Erlotinib is a potent inhibitor of the epidermal growth factor receptor tyrosine kinase,
with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of …
with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of …
Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial
U Gatzemeier, A Pluzanska, A Szczesna… - Journal of Clinical …, 2007 - cir.nii.ac.jp
< jats: sec>< jats: title> Purpose</jats: title>< jats: p> Erlotinib is a potent inhibitor of the
epidermal growth factor receptor tyrosine kinase, with single-agent antitumor activity …
epidermal growth factor receptor tyrosine kinase, with single-agent antitumor activity …
[引用][C] Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The tarceva lung cancer investigation trial
A PLUZANSKA, A SZCZESNA… - Journal of clinical …, 2007 - pascal-francis.inist.fr
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell
lung cancer : The tarceva lung cancer investigation trial CNRS Inist Pascal-Francis CNRS …
lung cancer : The tarceva lung cancer investigation trial CNRS Inist Pascal-Francis CNRS …